HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity.

Abstract
Honokiol is an active compound purified from magnolia that has been shown to induce cell differentiation, apoptosis, and anti-angiogenesis effects, as well as an enhancement in tumor growth delay in combination with chemotherapeutic agents in several mouse xenograft models. Our goal was to investigate the radiosensitization effect of honokiol on lung carcinoma. The radiosensitization effect of liposomal honokiol in Lewis lung carcinoma cells (LL/2) was analyzed using an in vitro clonogenic survival assay. For an in vivo study, Lewis lung carcinoma-bearing C57BL/6 mice were treated with either liposomal honokiol at 25 mg/kg or 5 Gy of single tumor radiation, or a combination of both over 12 days of treatment. The tumor growth delay and the survival time were evaluated. In addition, histological analysis of tumor sections was performed to examine changes by detecting the microvessel density and apoptosis in tumor tissues. In the clonogenic survival assay, LL/2 cells treated with IC(50) Lipo-HNK for 24 h showed a radiation enhancement ratio of 1.9. After 12 days of combination treatment, the tumor volume decreased 78% and produced an anti-tumor activity 1.3-fold greater than a predicted additive effect of honokiol and radiation alone. This combination treatment also caused an 8.7 day delay in tumor growth. The cell cycle distribution and histological analysis demonstrated that liposomal honokiol has an anti-tumor effect via inducing apoptosis and inhibiting angiogenesis. Liposomal honokiol can enhance tumor cell radiosensitivity in vitro and in vivo, indicating that radiotherapy combined with liposomal honokiol can lead to greater anti-tumor efficacy.
AuthorsJia Hu, Li Juan Chen, Li Liu, Xiang Chen, Ping Li Chen, Guang Yang, Wen Li Hou, Ming Hai Tang, Fan Zhang, Xian Huo Wang, Xia Zhao, Yu Quan Wei
JournalExperimental & molecular medicine (Exp Mol Med) Vol. 40 Issue 6 Pg. 617-28 (Dec 31 2008) ISSN: 1226-3613 [Print] United States
PMID19116447 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Biphenyl Compounds
  • Lignans
  • Liposomes
  • honokiol
Topics
  • Angiogenesis Inhibitors (administration & dosage, therapeutic use)
  • Animals
  • Apoptosis
  • Biphenyl Compounds (administration & dosage, therapeutic use)
  • Carcinoma, Lewis Lung (drug therapy, radiotherapy, therapy)
  • Cell Cycle (drug effects, radiation effects)
  • Cell Line, Tumor
  • Combined Modality Therapy
  • Humans
  • Lignans (administration & dosage, therapeutic use)
  • Liposomes
  • Lung Neoplasms (drug therapy, radiotherapy, therapy)
  • Magnolia (chemistry)
  • Mice
  • Neoplasm Transplantation
  • Neovascularization, Pathologic (drug therapy, radiotherapy)
  • Radiation Tolerance
  • Transplantation, Heterologous

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: